Immune Response in Peripheral Blood of Patients With Colon Cancer
|ClinicalTrials.gov Identifier: NCT00900432|
Recruitment Status : Completed
First Posted : May 12, 2009
Last Update Posted : December 3, 2015
RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that may occur in the immune system that may help kill cancer cells.
PURPOSE: This laboratory study is looking at anticancer immune responses in the peripheral blood of patients with colon cancer.
|Condition or disease||Intervention/treatment|
|Colorectal Cancer||Other: immunoenzyme technique Other: laboratory biomarker analysis|
- Quantify T cells specific for tumor peptides (carcinoembryonic antigen and MUC1) from the peripheral blood of patients with colon cancer.
OUTLINE: This is an open-label study.
Patients undergo blood collection at time of follow-up, surgery, thoracentesis, paracentesis, or leukapheresis (≤ 5 times per year). Blood is analyzed for tumor peptides (carcinoembryonic antigen and MUC1), circulating cytokines, and lymphocyte response by ELISA, ELISPOT, or intracellular flow.
PROJECTED ACCRUAL: A total of 140 patients will be accrued for this study.
|Study Type :||Observational|
|Actual Enrollment :||67 participants|
|Official Title:||Immune Studies of Peripheral Blood From Patients With Malignant Disease Gastrointestinal Tract|
|Study Start Date :||July 2004|
|Actual Primary Completion Date :||December 2008|
|Actual Study Completion Date :||December 2008|
- Quantitation of T cells specific for tumor peptides (carcinoembryonic antigen and MUC1) [ Time Frame: 3 months ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00900432
|United States, Arizona|
|Arizona Cancer Center at University of Arizona Health Sciences Center|
|Tucson, Arizona, United States, 85724-5024|
|Study Chair:||Michael Demeure, MD||University of Arizona|